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ABSTRACT
Addictive disorders/substance use disorders (SUDS) affect almost everyone in the United
States, either directly or indirectly. The cost of substance abuse to the social and economic
structure in the United States is huge. Anxiety is one of the most frequently mentioned
symptoms which lead to relapse during the early weeks of recovery due to neurohormonal
changes in the limbic system as well as cortisol production which occur during this time. Present
research in the treatment of anxiety in substance abuse and long term recovery is focused on
genetics and pharmaceuticals, however most pharmaceuticals produce sedation. Additional
therapies in early recovery, which decrease the symptoms of anxiety while enhancing cognitive
ability to learn and apply coping skills, are needed.
Purpose: The purpose of this dissertation was to identify the natural degradation of anxiety
symptoms occurring during the first few weeks following detox from alcohol or opiates. To
identify non pharmacological methods in use to decrease anxiety symptoms during this period,
and then examine whether treatment with Cranial Electrotherapy Stimulation (CES) would
enhance the degradation of anxiety symptoms.
Methods and Results: The initial prospective study of 53 men in residential treatment, measured
anxiety on entry, 30 and 60 days. The results found that increased anxiety measured prior to a
participant leaving against medical advice was more significant than increased anxiety measured
on admission. The follow-on pilot study in the same residential program was a double-blind
experimental study using CES with active and placebo CES units loaned from the manufacturer.
The intervention was conducted during the first 3 weeks of opiate/alcohol abstinence; a period
identified when anxiety peaks, and dropout rate is high. There were 29 men in the experimental
iii

group and 31 in the placebo group. Salivary cortisol and state anxiety were measured on the first
and final day of CES treatment. Anxiety was also measured at study enrollment and at 30 days
when study enrollment was terminated. The results were statistically inconclusive as both the
placebo and CES (experimental) groups trended downward; however the trend was greater in the
CES group.
Discussion/Implications: Anxiety was identified as a significant factor in leaving treatment
early. Cranial Electrotherapy Stimulation appears to decrease anxiety in non-substance abusing
populations. However, these finding were not supported in this substance abusing population
during the first month of recovery. Although CES appeared to be the most promising alternative
therapy, more research is needed in the use of this and other emerging therapies for the treatment
of anxiety symptoms during this early recovery period.
.
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CHAPTER 1: INTRODUCTION
Addictive disorders/substance use disorders (SUDS) affect almost everyone in the United
States, either directly through a family member, or indirectly through friends or acquaintances.
The cost of substance abuse to the social and economic structure in the United States is huge.
Indeed, more than $.5 trillion is spent annually in healthcare, and associated crime or accidents
(National Institute of Drug Abuse [NIDA], 2012). The personal cost to individuals is enormous,
ultimately affecting all dimensions of functioning, including poor health (Curtis, Zahs, &
Kovacs, 2013), poor interpersonal relationships, job losses, difficulty in school, as well as
financial or legal problems (Harris, Smock, & Tabor Wilkes, 2011). Entering and maintaining
recovery is a personal and ongoing struggle for most substance abusers. The treatment of
substance abuse is complex and long term with no single effective treatment modality and
involves collaboration between medical, psychiatric and social services.
The focus of this dissertation is gaining a better understanding of anxiety symptoms in the
first few weeks following substance withdrawal in patients suffering from alcohol and opiate
dependence. The aim of this research is to identify whether complementary and alternative
therapies and cranial electrotherapy stimulation (CES) in particular, has a role in the treatment of
anxiety symptoms during this period of early drug abuse recovery.
Addiction is a brain disease, which has been aptly described by Nora Volkow, Director of
NIDA, as ‘’the brain being hijacked’’ (Volkow, 2014). Youthful experimentation or adult
substance use to deal with stress, anxiety or pain (both emotional and physical) may lead to
physical and psychological dependence. The trajectory from use to abuse, and ultimate
dependence on one or more drugs, is due to a variety of physiological factors which are
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influenced by the individual’s genetic makeup and by life experiences which lead to changes in
the gene alleles (epigenetic changes). Most individuals never become physically or
psychologically dependent. However in those that are affected, the dependence may happen
with the first use, or develop slowly over a number of years. Most do not recognize their drug
dependence as a problem until it starts to affect personal, social, work and family relationships.
What is initially seen as a solution to life stressors ultimately becomes the stressor itself.
The Stages of Change Model as described by Prochaska and DiClemente (1984) has become
the working model for identifying substance abuse and starting treatment for the substance
abuser. Motivational interviewing is used to move an individual from pre-contemplation to
contemplating change in the substance abuse behavior. However, once the individual has made a
decision to change, and moves from the preparation phase into the action phase, multiple
obstacles line his path. Not all individuals need a medical detox but for those who do, protocols
and treatment are available and easily implemented. The hard work starts after this, with the
development of post-acute withdrawal symptoms which may be both physical and emotional.
This is early recovery. Anxiety is one of the most frequently mentioned symptoms which lead to
relapse during the early weeks of recovery (Levy, 2008) and is thought to be exacerbated by the
disequilibrium of dopamine and endogenous opioids within the limbic system (Sher, 2002) as
well as changes in the production of cortisol (Lovallo, 2006).
There is no single overarching theory which binds all the components of substance abuse.
Many theories have been developed by individuals (or scientists) within the healthcare
disciplines involved in the care and treatment of substance abusers. However, the Theory of
Allostasis is broad enough to address the biopsychosocial dimensions of this multifaceted
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disorder. Allostasis is conceptualized as a process that allows for ongoing evaluation and
neurochemical adjustments between internal and external psychological demands on the
individual (Ganzel, Morris, & Wethington, 2010). Allostasis is a central nervous system driven
response which integrates appraisal, coping, learning and memory into the physiological
response to these demands. Cortisol is produced when allostasis is not achieved and is a
response to fear.
In the substance abuser, allostatic accommodation occurs initially within the neural
circuitry of the limbic system in response to the drug of abuse, creating a drug dependent state of
allostasis. When the drug of abuse is withdrawn, allostasis is lost and there is a further
dysregulation of cortisol production (Koob, 2003) and therefore increased symptoms of anxiety.
Present research in the treatment of anxiety in substance abuse and long term recovery is
focused on genetics and pharmaceuticals. The goals of most research are to reverse epigenetic
changes associated with continued substance abuse, block negative memories and fully map the
relationships of drugs to the limbic system (Nestler, 2014).
Group and individual psychotherapy has been the mainstay of substance abuse recovery for
many years. Epigenetic changes occurring during psychotherapy are well documented (Feinstein
& Church, 2010). Pharmacological agents presently used to attenuate symptoms of anxiety
during withdrawal often have side effects which limit the efficacy of treatment, and in the
recovery period, often are not used long term due to cost and limited effectiveness. Treatment
with somatic and complementary methods (CAM) has been used in an adjunct capacity for many
years in substance abuse and offers potential long term options.
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The current state of the science of non-pharmacological therapies used for the treatment of
the symptoms associated with anxiety during substance abuse withdrawal is discussed in Chapter
2 of this dissertation. Specifically discussed are somatic and complementary therapies (CAM) as
used in the various Stages of Change Model (Prochaska & DiClemente,1984) within the
continuum of substance abuse treatment. These therapies include acupuncture, massage therapy,
meditation, yoga and music. Also identified are somatic therapies involving electrical and
magnetic stimulation of neurons in the limbic system which have emerged as potential
treatments for substance use disorders and the associated negative symptoms such as anxiety.
These modalities include deep brain stimulation, transcranial magnetic stimulation, direct current
stimulation and cranial electrotherapy stimulation (CES). Case studies with good results using
these modalities have provided the impetus for further research into their effects on substance
abuse and associated anxiety symptoms. However, the research is not broad with a limited
number of studies completed.
In chapter 4 of this dissertation a study completed prior to the CES study discussed in
Chapter 3, is presented. The use of present ‘standard of care’ treatment and subsequent changes
in anxiety was examined during a single group repeated measures study of anxiety during the
first two months of substance abuse treatment of men in the same treatment facility. Results in
this study identified that anxiety is a significant factor in relapse during the first two months of
treatment and that individuals with persistent anxiety were less likely to complete treatment than
those whose anxiety remitted during the first few weeks after detox.
Decreasing the anxiety associated with post-acute withdrawal, is one of the components
critical to insuring that patients continue on the recovery path. In Chapter 3, a Randomized
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Controlled Trial (RCT) using CES conducted during the second to fourth weeks following detox
is reported. This research was conducted with a group of 56 men in a residential treatment
facility that had recently completed a medical detox from either alcohol or opiates. Anxiety and
cortisol responses were measured during the treatment phase. Cranial electrotherapy stimulation
(CES) is a somatic treatment that has been used for many years in the treatment of generalized
anxiety and was identified as a modality which could be easily used in a recovery program with
minimal training of both staff and patients. No recent studies have been reported on its use in
decreasing anxiety in early substance abuse recovery. Although CES may be effective in
reducing anxiety and cortisol response in this population, it was not demonstrated in this study.
Psychopharmacological medications as well as placebo effect may have confounded the results.
The research results in this dissertation have extended the knowledge of the effect of anxiety
symptoms on treatment dropout. This research also identified an alternative therapy in CES
which may be effective in decreasing anxiety in early recovery in specific substance abusing
populations. However further research is needed in the use of CES to identify whether higher
anxiety at intake and earlier use of CES in opiate abusers would cause greater symptom
attenuation. Recommendations regarding focus of treatment for anxiety were made based on the
results of these studies and are being implemented in the residential facility where the research
was conducted.
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CHAPTER 2: THE ROLE OF COMPLEMENTARY AND ALTERNATIVE THERAPIES
IN SUBSTANCE ABUSE RECOVERY: A STATE OF THE SCIENCE PAPER

Psychotherapy and 12 step programs have been the cornerstone for substance abuse
treatment for the last 75 years. Since the 1960s, substance abuse has slowly moved from being
viewed as a moral failing to being recognized as a disease with a physiologic basis. As such,
research in treatment has gradually moved the treatment focus to pharmacological solutions.
Although progress is being made in identifying pharmacologic treatments for detox and
recovery, attaining and sustaining recovery from substances of abuse remains a challenge, with
many persons relapsing within 2 weeks of detoxification (Chutuape, Jasinski, Fingerhood, &
Stitzer, 2001) and less than 50% remaining in recovery at 6 months (Gil-Rivas, Prause, &
Grella, 2009). In fact, little improvement has been noted since the 1980s in achieving sustained
recovery (Dennis, Foss & Scott 2007).
During these and subsequent years, there has been a renewed interest in all alternative and
complimentary modalities as potential tools for decreasing symptoms associated with substance
withdrawal, as well as increasing time in recovery. Acupuncture, massage therapy, yoga,
meditation, exercise and music are often integrated into substance abuse treatment. Other
emerging modalities involving somatic interventions include Transracial Magnetic Stimulation
(rTMS), Deep Brain Stimulation (DBS), Direct Current Stimulation (DCS), and Cranial
Electrotherapy Stimulation (CES). These are presently used to treat mood disorders and may
also have a role in substance abuse treatment. The purpose of this state of the science paper is to
explore the current research and use of complementary and alternative therapies (CAM) as well
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as other non-pharmacological somatic modalities which may have a role in decreasing anxiety in
substance abuse recovery treatment.
Scope of the Problem
Long term recovery from substance abuse is often an elusive goal for many people. The
cost of abuse, detox, recovery and relapse is a financial burden to our society ((National Institute
of Drug Abuse [NIDA], 2012) as well as to families and individuals struggling with substance
abuse.
The burden of substance abuse often starts with youthful experimentation, early addiction
and often accidental death. Substance abuse often stems from traumatic childhood experiences
and mental health disorders, precipitated by genetic vulnerability (McQuown &.Wood, 2010).
This vulnerability may be either enhanced by nature (genetic) or nurture (epigenetic) as has been
described by social and biological scientists (Feinstein & Church, 2010; Nestler, 2014). This
genetic effect continues into adulthood and often into the work environment. It is manifested by
the negative consequences related to substance abuse which may include poor health, poor
interpersonal relationships, job losses, difficulty in school, and financial or legal problems
(Harris, Smock, & Tabor-Wilkes, 2011). Most individuals with substance use disorders
experience some of these problems during their time in active addiction.
Adults in the prime of life often use opiates to cope with chronic pain. Alcohol and
cannabis have been used for millennia to cope with stress and anxiety. Many persons become
marginalized in our society as the substance of abuse affects their social and work lives (Darke,
2012). Substance abuse is a complex issue. The genetic influence of substance abuse extends
far beyond the direct effect of the drug on the affected neurotransmitter and the up or down

9

regulation at the neuronal synapses (Solinas, Thiriet, Chauvet, & Jaber, 2010). Epigenetic
changes associated with alcohol abuse are implicated in the attenuated immune response as is
found in chronic inflammation and delayed response to infection. This is manifested in higher
rates of pneumonia, hepatitis C progression and liver cancer, as well as affecting the health of
many other organ systems within the body. (Curtis, Zahs, & Kovacs, 2013).
Not even our elderly are spared the effects of substance abuse, struggles with recovery and
subsequent relapse. Alcohol abuse has long been recognized as increasing with aging and at
retirement (CSAT, TIP #26, 1998). It is often in this later phase of life that alcohol abuse is
identified by family members as being problematic, interfering with social and family life.
Opiate use for non-medical and non-cancerous pain also increases in older adults (NSDUH,
2009). The elderly with substance use disorders are also more likely to have co-morbid
psychiatric conditions and generally be in poorer health (Taylor & Grossberg, 2012).
Present Best Practices
The most successful model for substance abuse recovery in the past 75 years has been
Alcoholics Anonymous (AA), or some variation of the 12 step program (Kaskutas, 2009). Used
in many recovery programs as well as in the community, AA is useful for many substance
abusers and is widely accessible (Miller, Sorensen, Selzer, & Brigham, 2006). However, it is
not an effective model for all people as long-term recovery remains elusive for many (Dennis et
al., 2007). Other individual and group psychotherapy treatments are also effective in decreasing
the incidence of relapse (Finnerty, 2012), especially when used in conjunction with
pharmacological treatment.
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Medical management tends to be short-term and often not sustainable due to cost and
intensity of management both by participants and the health care system. This is evidenced by
the high percentage of individuals who cycle through substance abuse treatment and mental
health facilities on a continual basis (Finnerty, 2012). Long term medical (pharmaceutical)
management of substance abuse is limited to opiate replacement therapies such as methadone or
buprenorphine maintenance. Many people also cycle in and out of these highly intensive and
costly programs. The use of disulfiram, acamprosate and naltrexone in alcohol recovery is often
limited to weeks or months (Seneviratne, & Johnson, 2015), and without supportive care has
very little impact on length of recovery.
Over the past 2 decades, addiction research has focused on both neurochemicals and
genetics. The role of genetics and the hypothetical ability for the reversal of epigenetic changes
has become a primary focus for further research in sustaining substance abuse recovery (Nestler,
2014). The other focus at present is through pharmacological advances. However, counseling
and behavioral change strategies also have a known long term impact on sustained recovery and
gene reversal (Carroll & Rounsaville, 2007; Feinstein & Church, 2010). The emerging
modalities involving the somatic interventions of Transcranial Magnetic Stimulation (rTMS),
Deep Brain Stimulation (DBS), Direct Current Stimulation (DCS), and Cranial Electrotherapy
Stimulation (CES), are presently used to treat mood disorders (Rosa & Lisanby, 2012), and may
also have a role in substance abuse treatment. Other Complementary and Alternative Medicine
(CAM) somatic therapies also have an adjunct role in substance abuse recovery.
A literature search was conducted using EBSCO and PSYCINFO. Only articles written in
English were reviewed and were limited to studies published since 1980. Key words included

11

substance abuse, anxiety and each of the identified treatment modalities. One thousand and nine
abstracts were reviewed and the results of thirty studies were included in this review. This
review includes seminal studies when identified and systematic reviews when available. Studies
with similar methods and outcomes were not included (See Table 1).

Table 1: Measures and results for CAM studies
Reference

Population

Sample
Size

Study Type

Length of
study

Measures

Outcome

Interview
post
treatment
Post
treatment
interview

Improved
anxiety

Acupuncture
Alster 2010

recovery
program

100

Qualitative

1 year: 3-6
treatments

Bergdahl et al 2014

Residential early
treatment

15

Qualitative

Unknown

Bearn et al 2009

During opiate
detox

83

RCT (2 groups)
acupuncture and
TAU control

14 days

SOWS

Black et al 2011

Early
withdrawal

101

RCT (3 groups)
Acupuncture,
sham and
relaxation

3
treatments
over 2
weeks

STAI

Chang et al 2014

Veterans in
recovery

67

RCT (3 groups)
Acupuncture ,
relaxation and
TAU

10 weeks
2
acupuncture
sessions
weekly

STAI

Decreased
anxiety in
both
treatment
groups

Recovery
program

31

Qualitative
(Mindfulness)

5 months

Pre post
test
ASI

No better
than TAU

Decrease in
anxiety
during
treatment
No
difference
between
groups
Decrease in
anxiety in all
groups

Massage,
meditation and
Yoga/mindfulness

Alterman et al
2004
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Sample
Size

Length of
study

Measures

Outcome

RCT (2-groups)
Chair massage
and relaxation

3 days

STAI

67

RCT (3-groups)
(relaxation,
acupuncture and
TAU

STAI

248

RCT (2 group
)meditation/yoga
vs relaxation

10 weeks
45 mins per
week of
relaxation
therapy
2 weeks

various

various

1st 4 days of
Alcohol
withdrawal
Various

AWS

State anxiety
sustained for
24 hours in
CM group
Decreased
anxiety after
2 weeks in
treatment
groups
Decreased
anxiety after
2 weeks both
groups
Studies
generally
weak
Decreased
pulse after
15 minutes
Improvement
in stress
symptoms.
Decrease in
sympathetic
activity
MBSR p<
0.000 and
CBSR p
<0.013

Reference

Population

Black et al 2010

Recovery
program

40

Chang et al 2014

Veterans in
recovery

Chen et al 2010

Substance abuse
recovery

Ospina et al 2008

All CAM in
recovery

Reader et al 2005

Alcohol
withdrawal

Khanna et al 2013

Preparation
Phase for
Substance abuse
treatment

Smith et al 2011

Community
Volunteers

50

RCT (2 group)
Mindfulness
Stress reduction
and Cognitive
Behavioral Stress
Reduction

Bonny 1986

Substance abuse

unknown

Qualitative

Chaieb et al 2015

Various

30
articles

Qualitative
review (binaural
beats)

various

various

Mays et al 2008

Substance abuse
treatment

unknown

Qualitative
review
Of 5 studies

Adjunctive
therapy

interview

50

Study Type

Systematic
review
400 RCTs
RCT (2 group)
Massage therapy
and TAU
Qualitative
review

8 weeks

STAI

Various

Perceived
Stress
Scale –
pre and
post tx

Music Therapy

Trans cranial
Magnetic
Stimulation

13

Evokes
emotions and
physiological
response
Modulating
mood states
with regular
sessions
Felt was
“helpful”

Study Type

Length of
study

Measures

Outcome

Systematic
review 19 studies

DLPFC per
protocol

Interview,
VAS

Systematic
review 18 studies

DLPFC per
protocol

VAS

45

RCT Single
blind with
placebo group

R DLPFC
per protocol
10 sessions

40

RCT double
blind to R and L
DLPFC

Per
protocol 10
sessions

ACQNOW, pre
post and 1
month
ACQNOW
Same time
points

Substance abuse.
Active users

Systematic
review
9 RCTs. Placebo
controlled. 3 with
Alcohol

Various R
or L
DLPRC

Various

May be
promising to
decrease
craving
11 studies
supported
decreased
craving
Measured
craving only
Significant
decrease
No
difference
between
groups.
Craving
decrease
significant
Decrease
craving for
alcohol in
active group

Substance
abusers

Systematic
review 8 RCTs
TMS with DCS

Various

Various

Decrease
craving in
both groups

12

Open label

6 weeks

HAM-A

115

RCT double
blinded

5 weeks

HAM-A

50% with
decrease in
anxiety
85% with
decrease in
anxiety

Length of
study

Measures

Reference

Population

Gorelick et al 2014

Substance abuse
treatment

Grall-Bronec et al
2014

Substance abuse
treatment

Mishra et al 2010

Alcohol
dependence

Mishra et al 2015

Alcohol
dependence

Jansen et al 2013

Sample
Size
316

Transcranial
Direct Current
Stimulation
Jansen et al 2013

Cranial
Electrotherapy
Stimulation
Bystritsky et al
2008
Barclay et al
2014

Generalized
anxiety in
outpatient
Anxiety in
Primary care

Reference

Population

Sample
Size

Study Type

14

Outcome

Kirsh et al 2007

335

Krupitsky et al
1991

Substance
abusers
Alcohol
withdrawal

20

Meta analysis
15 studies
RCT

Overcash et al
1989

THC
withdrawal

32

Open label

Rose et al 2009

Caregivers of
Alzheimers
patients
Polysubstance
abuse in
treatment
Dental office
During
procedure

42

RCT Double
blind

60

RCT double
blind

33

RCT Double
blind – placebo
and CES

Schmitt et al
1986
Winick 1999

various

various
STAI

30 days

Ham-A

STAI

Single
treatment

VAS at 3
time
points

Decrease in
anxiety
Robust
Decrease in
anxiety
Robust
decrease in
anxiety
No change
in
symptoms
Robust
decrease in
anxiety
Significant
decrease in
anxiety

Complementary and Alternative Medicine

Acupuncture
Acupuncture has been used as a modality for the treatment of multiple conditions in China
for several thousand years (Myatt, 2005). It is believed that endogenous opioids play a role in
acupuncture analgesia and are released during acupuncture. Acupuncture is also thought to
stimulate the hypothalamus and pituitary, resulting in a broad spectrum of neurotransmitter and
neurohormone release; most importantly, the endogenous opioids and subsequent cascade to
release of ACTH and then cortisol release (Lui, Li, Xia, & Terplan, 2009). This is conceptually
similar to the gate theory of pain which was first described by Melzack and Wall (1965). The
NIH Consensus Statement on Acupuncture (1997) advised that “there is sufficient evidence of
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acupuncture’s value to expand its use into conventional medicine and to encourage further
studies of its physiology and clinical value” (Conclusion section, para. 5).
The NIH Consensus Statement (1997) also discussed multiple other factors that make
research studies on the use of acupuncture difficult as many other factors may profoundly affect
the therapeutic outcome. These variables are described as the relationship between the patient
and the clinician, the amount of trust developed in the relationship, the expectations of both the
patient and the clinician, as well as the belief systems of both individuals. These variables set
the tone for the therapeutic relationship and contribute to the outcome of the (acupuncture)
treatment (NIH, 1997). These same psychosocial parameters which affect treatment outcomes in
acupuncture also affect outcomes in substance abuse treatment. Indeed, acupuncture has been
used successfully in substance abuse treatment for more than 35 years (Cai-Lian, Liu-Zhen, &
Fei, 2008). This is consistent with the NIH Consensus Statement (1997).
Most recent studies have focused on auricular acupuncture using a protocol developed by
the National Acupuncture Detoxification Association (NADA). This protocol, using 5 needles
placed at specific points in the ear auricle, is thought to improve retention in treatment by
decreasing drug cravings, anxiety and lessening physical symptoms of withdrawal (Carter &
Olshan-Perlmutter, 2014). However, research regarding the use of auricular acupuncture in
substance abuse treatment, remains limited without clear outcomes in many studies.
Chang and Sommers (2014) reported on a study where auricular acupuncture was compared
to relaxation response in a 10 week study on reducing craving and anxiety in veterans recovering
from substance abuse. Results indicated substantial decreases in anxiety and craving following
an individual session of acupuncture (p <.001) or relaxation response (p<.03), with craving
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continuing to drop with continued sessions. However, it was not determined whether it was the
regular attendance or daily practice of relaxation response techniques that elicited the change
(Chang & Sommers, 2014). Similar concerns have been voiced by other researchers (Alster,
2010; Bergdahl, Berman, & Haglund, 2014).
In another recent Randomized Controlled Study (RCT) of 101 patients in substance abuse
treatment (Black, Carey, Webber, Neish, & Gilbert, 2011), the hypothesis that auricular
acupuncture would be effective in reducing anxiety was not supported. Anxiety was measured
using a pre and post-test design. Participants were randomized into 3 groups: active auricular
acupuncture using the NADA protocol, sham acupuncture, and relaxation therapy. Each
received 3 treatments over 2 weeks. There was a significant drop in state anxiety in all treatment
groups (p<.001) immediately following each treatment but there was no difference between each
of the groups.
When auricular acupuncture was used during a 14 day opiate detox using methadone,
auricular acupuncture was not found to decrease opiate withdrawal symptoms in a study of 83
participants (Bearn et al., 2009). In this RCT, participants were randomized into control and
acupuncture groups. Demographics in both groups were statistically similar. There were no
significant differences in the severity of withdrawal symptoms between the 2 groups.
An observational study on the use of auricular acupuncture in a residential treatment
program was described by Martin Alster (2010). In this setting, auricular acupuncture, using the
NADA model was implemented 1-3 times weekly along with mindfulness meditation. Most
clients received 3-6 treatments. Non-specific benefits included feelings of contentment and
relaxation. More specific improvements in symptoms included better sleep, reduced cravings
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and anxiety as well as general improvement of mood. Negative reports voiced by participants
were occasional feelings of lightheadedness or burning at the needle site. The staff were
concerned that the treatment was time-consuming and labor-intensive. The staff also observed
that the group dynamic was a factor in both the participants’ willingness to participate or, in
some cases, their refusal to do so.
In another qualitative study (Bergdahl et al., 2014) similar findings of increased relaxation,
feelings of well-being, peacefulness and harmony, as well as decreased anxiety and drug use
with auricular acupuncture were reported. Concerns voiced by the participants were that the
process was time consuming, the effect was short-term, there was dependence on someone else
to give the treatment, and that cravings remained after treatment termination.

Massage, Meditation and Yoga
Many other modalities involving relaxation have been used to decrease the anxiety and
stress symptoms associated with substance use withdrawal. Studies generally report
improvement of symptoms but difficulties identifying appropriate control groups continue to
plague these studies.
A study of chair massage (N=40) over 3 days was compared to relaxation therapy (N=42) as
the control condition (Black et al., 2010). Participants were recovering from alcohol, cocaine or
opiate withdrawal. Anxiety was measured using the Speilberger State /Trait Anxiety Inventory
(STAI). Anxiety was reduced in both groups but to a greater extent in the Chair Massage (CM)
group (state, p= 0.001 and trait p=0.045). The state anxiety decrease was sustained for over 24
hours in CM, but not in the relaxation therapy control group. Standard counseling and
pharmacological management were also included. Standardized procedures were used for each
18

group to include the same time each day, same length of time, same room, same physical lighting
and the same staff member in the room. There was no physical contact with the participants.
Content validity and internal consistency of STAI (r=0.83) as well as benchmark for anxiety
were addressed. Heart rate response demonstrated no significant difference. An incidental
finding of a mean downward trend in diastolic blood pressure was observed in both groups
(p>.0001). This may have been related to a physiological response to decreased anxiety but was
not addressed by the author.
Another study of massage therapy identified a reduction in anxiety and also in heart rate
(Reader, Young, & Connor, 2005). This study of patients during the first four days of alcohol
withdrawal identified a decrease in pulse rate of 3-4 beats per minute after 15 minutes of upper
body massage. The control group was treatment as usual. However there was no comment on
how long the lower pulse rate lasted. The confounder of increased attention to the participants
could have affected the results (Reader et al., 2005).
Meditation has also been extensively used in substance abuse treatment. A study using
qigong meditation (QM) was compared to stress management and relaxation training (Chen,
Comerford, Shinnick, & Ziedonis, 2010). Chen et al. (2010) described QM as an interaction of a
variety of Chinese exercises and therapies, described as integrating body, breath and mind into
‘oneness’. Yoga and transcendental meditation are considered forms of QM. The process
includes slow abdominal breathing, inward attention, guided imagery and focus on maintaining
an ‘empty mind’. Participants in both groups followed recorded instructions. This study showed
no significant difference in state anxiety between the stress management and relaxation training
group and the QM group. Both groups noted decreased anxiety at the end of two weeks. The
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expected decrease in anxiety over time was not addressed. Individuals with low group
participation had more anxiety at the end of week two than participants who regularly attended
either of the two treatment groups. The participants also discussed the barriers they identified to
completing the meditation program. Comments included “too much for me”, “too much on my
mind”, “cannot concentrate”, “not sure how it can help”, “should not occur during free time”.
Many participants would have liked to have had the yoga integrated with regular activities, not as
an additional activity. There was no discussion on increased time in recovery.
Mindfulness meditation has also been studied in substance abuse recovery (Alterman,
Koppenhaver, Mulholland, Ladden, & Baime, 2004). In this study, meditation did not affect the
results of the Addiction Severity Index (ASI) when measured over 5 months during the patients’
stay in residential treatment for substance abuse. (N=31). With mindfulness meditation,
breathing is used as the focus of attention for meditation. Emphasis is placed on paying attention
to restlessness and irritability, then attempting to calm physiological responses of the body and
calm the mind. In this population, extra attention was placed on managing impulsivity and its
relationship to substance abuse. There was no evidence that this training had better outcomes
than treatment as usual. However, the authors commented that this treatment might be more
helpful in specific populations such as those with higher interest in religiosity or spirituality.
The relationship of spirituality to the effects of mindfulness and yoga was described by
Khanna and Greeson (2013). Their review of complementary treatments in substance abuse
found support for the use of yoga in conjunction with mindfulness in treatment. This
combination of therapies appeared to enhance recovery from addictive disorders, by targeting
stress-related cognitions, emotions, and drug craving. There was also evidence that when yoga
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and meditation targeted individuals with high spirituality there was a significant decrease in
cortisol production (31%) after each session that was not found in those who used yoga for
physical exercise only (Smith, Greer, Sheets, & Watson, 2011). Yoga was often referenced as an
adjunct activity available in recovery programs and also in therapy sessions for individuals still
in the preparation phase of substance abuse recovery (Chen et al., 2010, Khanna & Greeson,
2013). Unfortunately, no RCTs specifically involving yoga were found related to substance
abuse recovery treatment.
Ospina et al. (2008) completed a systematic review of meditation clinical trials between
1956 and 2005 including mindfulness, yoga, T’ai chi and QM. Issues with many studies
included publication bias, empirical evidence varying between the quality of the study and the
effect of treatment, self-selection into groups, motivation to participate as well as difficulty in
blinding both the control and experimental groups. The authors felt there were threats to
validity at all levels despite statistically significant improvements in many studies (Ospina et al.,
2008).

Music Therapy
Music has been used as an adjunct therapy in substance abuse treatment for many years.
A systematic review by Mays, Clark, and Gordon (2008) identified music as an adjunct therapy
in 5 studies with participants generally feeling that music was ‘helpful’. Reports were qualitative
and no RCTs were available. Bonny in her seminal writing in 1986 identified music as a nonverbal therapy which activated emotions and a physiological response, produced symbolic
images and enhanced the other senses. However, only 14% of substance abuse treatment
programs offer music therapy (Aletraris, Paino, Edmond, Roman, & Bride, 2014). More recently
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there has been renewed interest in the concept of binaural beats imbedded in music having an
effect on mood. In this systematic review (Chaieb, Wilpert, Reber, & Fell, 2015) there was some
evidence of decreases in both state and trait anxiety with regular sessions, however no RCTs
have been published related to substance abuse recovery. The authors mentioned that further
research was needed to identify neural mechanisms as well as sound ranges most likely to be
effective (Chaieb et al., 2015).

Other Somatic Treatments
During the past decade there has been renewed interest in the use of modulating
neurohormones through the use of electrophysiology. Manipulating behavior and cognition
through the use of electrical currents has been used for over 70 years, primarily as
Electroconvulsive Therapy (ECT) for the treatment of severe depression. There was some
interest in the effect of ECT on substance abuse in the 1990s. However, individual positive case
studies (Pearlman & Savanin, 1999) did not lead to RCTs indicating effectiveness on a broader
scope (Moss, & Vaidya, 2014). More positive results have been identified using other
modalities.

Deep Brain Stimulation
Deep Brain Stimulation (DBS), a neurosurgical procedure involving the placement of
directed electrodes within the brain, has been developed to treat movement disorders such as
Parkinson’s disease and other neurological conditions associated with severe tremor. The
electrical stimulus appears to interact with the corticostriatal circuits and associated neurons (also
highly implicated in substance abuse) but the exact mechanism of action is unknown (Soyka &

22

Mutschler, 2015). Pierce & Vassoler (2013) theorized that targeting the nucleus accumbens and
sub thalamic nucleus may hold promise for an effect on substance abuse. Although individual
reports and case studies have been reported in which an effect on substance abuse was found,
completing an RCT has proven difficult as patients are reluctant to enroll for this invasive
procedure (Luigjes, Brink, Schuurman, Kuhn, & Denys, 2015). More research studies are
available using non-invasive technologies.

Transcranial Magnetic Stimulation
About 20 years ago Trans-cranial Magnetic (TMS) therapy was introduced and studied for
the treatment of depression and other neurocognitive disorders. It is presently FDA approved for
use in resistant depression. Repetitive (r) TMS is based on the theory that a magnetic field
passing through the cranium, induces an electrical field that can alter neuronal activity. The
primary target for rTMS in the treatment of substance uses disorders is the dorsolateral prefrontal
cortex (DLPFC) (Gorelick, Zangen, & George, 2014). The DLPFC assists in the regulation of
the limbic system through its involvement in higher-order executive functions such as selfcontrol and being aware of behaviors and related events which are intimately involved in
substance abuse (Goldstein & Volkow, 2011). Interest in rTMS in substance abuse occurred
after the publication of case studies of patients exposed to this therapy for depression who noted
improvement in their craving symptoms. This has led to further research studies.
Jansen et al. (2013), in a meta- analysis, reviewed 9 sham controlled studies involving
substance abuse. Three studies involved alcohol use and identified an effect on craving
reduction (p = .06). There were no differences in craving reduction across other substances:
nicotine, and food. These studies involved active substance abuse rather than individuals in
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recovery. In another literature review, Grall-Bronnec, and Sauvaget (2014), identified 18 studies
using rTMS to treat substance abuse. Eleven studies supported the efficacy of rTMS in the
reduction in craving which was usually measured using a visual analog scale (VAS). However,
these effects were short-term which was thought to limit the effectiveness of the treatment. A
small RCT identified a decrease in alcohol craving in a single blind, sham controlled study of 45
patients with alcohol dependence (Mishra, Nizamie, Das, & Praharaj, 2010). Thirty patients
were in the active group. High-frequency rTMS to the right DLPFC was used for a total of 10
sessions. Alcohol craving, using the Alcohol Craving Questionnaire (ACQ-NOW) was
measured at base line, after the last rTMS session and 1 month later. Effect size for treatment
with time was moderate (r = 0.401). Decrease in craving at 30 days was significant (p<0.0005).
This study was criticized due to concerns regarding placebo effect, the use of rTMS only on the
right DLPFC as well as limiting measurement to subjective identification of craving (Trafton,
2010).
A subsequent study was conducted by Mishra, Praharaj, Katshu, Sarkar, and Nizamie,
(2015) in an attempt to decrease this criticism. This study was double blinded using 20 patients
with alcohol dependence syndrome randomly assigned to receive rTMS over either the right or
left DLPFC, using the same settings as in the previous study. Measurement was the ACQ-NOW
at the same time points. The results showed no difference between groups and time but did
identify significant reduction in craving scores in both groups over time (p < 0.0001).
Use of rTMS in substance abuse recovery shows promise. However the limitations with
the present studies include no references to, or identification of, long term recovery or use of
repeated treatments over extended periods. Transcranial magnetic stimulation appears to be a
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safe modality based on use for psychiatric disorders but more research is needed before moving
this modality into substance abuse treatment.

Transcranial Direct Current Stimulation
Transcranial direct current stimulation (tDCS) is a recent addition to the
electrophysiological tool box of substance abuse treatment modalities. This method (tDCS) was
initially researched in the 1960’s; however no significant results were published. Little research
was reported until the past decade when results of research involving rTMS stimulated renewed
interest in tDCS. Direct current stimulation is applied using a simple devise, obtainable on the
internet and charged with a 9 volt battery. This devise provides a very low direct current (1-2
mA) in a single direction from the anode to the cathode attached to the cranium with saline
moistened sponges and a strap (Rosa, & Lisanby, 2012). The focus of current research is also on
applying the current to the DLPFC and the subsequent effect on cognition, mood and behavior.
Few research studies using tDCS relating to substance abuse and craving are available.
Jansen et al (2013), in a meta-analysis of 8 studies of tDCS compared results of rTMS to
tDCS, and found comparable decreases in alcohol craving (z = 5.832, p < 0.001). These devices
are not FDA approved for any specific disorder, however, they are available without a
prescription from multiple internet sources. They are advertised as providing low level electrical
current to the brain for various neurocognitive problems.

Cranial Electrotherapy Stimulation (CES)

25

Cranial Electrotherapy Stimulation was developed in the Soviet Union in the 1950s and has
been used in the United States since the 1960s, initially as a treatment method called ‘electro
sleep’. Low level (100 to 600 microamps) micro current is given to the patient through
electrodes placed on the earlobes for a varying amount of time (Kirsh & Smith, 2000). The
device is presently used in the Veterans Administration System (Tan, Dao, Smith, Robinson, &
Jensen, 2010) and by psychologists in general practice for the ancillary treatment of pain,
anxiety, depression and insomnia, (Kirsh, & Gilula, 2007). Research protocols in a variety of
patient conditions have varied from a single treatment, a one hour treatment weekly to 20-30
minute sessions daily over several weeks. Initial CES studies focused on anxiety in a substance
abusing population were conducted 20 years ago (Schmitt, Capo & Boyd, 1986; Overcash &
Siebenthall, 1989; Krupitsky et al.,1991). Results in all these studies were described as
statistically significant, although only Krupitsky et al. (1991) identified a p value (p<.05). No
negative side effects were identified. However, no recent studies have been conducted to
evaluate relief of anxiety in substance abuse withdrawal.
The use of CES in Generalized Anxiety Disorder has also been studied (Bystritsky,
Kerwin, & Feusner, 2008). In a small open label study (N = 12), participants ranging in age
from 29-58 years were recruited from the community. All received an active CES unit. There
was no control group. CES was administered for 6 weeks using a 0.5-Hz frequency and a 300-u1
A intensity. Both the Hamilton rating Scale for Anxiety (HAM-A) and the Clinical Global
Impressions-Improvement scale (CGI-I) were used to measure anxiety pre- and post-treatment.
Fifty percent (6 patients) had a 50% decrease in the HAM-A (p = .01) and a rating of 1 or 2 on
the CGI-I (much improved, or very much improved). An additional patient had significant
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improvement in anxiety score but did not meet criteria for the study standard. Adverse events
mentioned were mild headache or nausea. A limitation of the study mentioned by the authors
was the small sample size and that it was open label, which may have impacted on the results.
A similar study by Barclay and Barclay (2014) evaluated CES in a group of primary care
patients (n=115) with anxiety disorders. In this double blinded study, participants were recruited
from the community and paid $30 to enroll in the 5 week study. Individuals in the placebo group
were given an opportunity to use the active unit following their completion in the study. In this
study, 85% of the participants in the active CES group had an overall reduction in anxiety at
study termination. The average reduction was 32% from anxiety baseline as measured with the
HAM-A (F=43.401, df =1 p=.001, d=.94).
Other researchers have also reported positive study results using CES. A double blinded
study using CES to decrease anxiety during dental procedures is often referenced (Winick,1999).
In this study (N=33), 17 patients were randomized to the experimental group using CES at 0.5
Hz and a sub sensory A setting of 200-u1, while the 16 patients in the placebo group had sham
CES units. The manufacturer did not release the codes for active or placebo units until after the
study was completed. Measurement was a 7 point Likert scale which rated the degree of
improvement of anxiety at completion of the procedure and a Visual Analog Scale (VAS)
measuring anxiety from ‘not anxious’ to ‘very anxious’. The measurements were taken at 3 time
points during the procedure: prior to initiation, midway, and at completion. Both the dentist and
the patient completed both ratings at each time period. (The dentist rated his perception of the
patient’s anxiety). Results of the VAS for both patient and dentist observer indicated decreased
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anxiety in experimental group when compared to the placebo group (p < .02) and this was
corroborated with the Likert results ( p < .01) (Winick,1999).
Another double blind study examined the effect of CES on sleep and depressive symptoms
in 42 care givers of patients with Alzheimer’s disease. This study found no statistically
significant differences between the placebo and experimental groups (Rose, Taylor, &
Bourguignon, 2009), although there was trending towards significance on the sleep index. The
authors felt that a limitation was that the study was underpowered.
Empirically, CES appears to assist in bringing neurotransmitters back into homeostasis.
However, the exact mechanism of action remains unclear. This effect is thought to be due to the
effect on the parasympathetic nervous system through stimulation of the auricular branch of the
vagus nerve (Kirsh & Gilula, 2007). By changing the electrical and chemical activity in the
brainstem, CES appears to amplify activity in some neurological systems and diminish activity in
others. Critique of many studies included low power due to few participants, methodological
differences and difficulty controlling for multiple variables (Bystritsky et al., 2008; Rose et al.,
2009). Although CES has been studied in patients with various anxiety related disorders, and
appears to be effective, no recent studies have focused on anxiety in the period of early substance
abuse recovery.
Summary
The heterogeneity of substance abuse and its effect on individuals is a conundrum for
researchers. The thread throughout these presented studies is that RCTs are difficult to conduct
due to the multiple variables associated with individuals in recovery for substance abuse.
Demographics may be similar, as may be the substance of abuse, but each individual comes with
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his or her own genetic makeup and unique epigenetic changes. Although RCTs remain the gold
standard for research, they are challenging to complete or reproduce in substance abuse treatment
due to multiple variables associated with small treatment populations in individual recovery
programs. This heterogeneity of substance use disorders with the widely differing individual
responses to treatment portend a need for individually developed treatment plans. As research
moves into practice, it is critical that all potential modalities which may enhance epigenetic
reversal, and improve the sustainability of substance abuse recovery be assessed for use in each
individual. Most but not all of these complementary modalities have been found to decrease
either anxiety or craving in specific individuals with substance use disorders. Cranial
electrotherapy stimulation is a modality that seems especially promising since it does not require
individual monitoring or specialized group attendance, and if effective may be used by
individuals on an ongoing basis. The effect of CES on decreasing anxiety in non-substance
abusing populations appears to be robust. This effect may also be apparent in substance abusing
populations. However previous studies in early substance abuse recovery are limited and have
not been replicated in many years. Research in all these modalities should be continued, and
when found effective, be implemented into practice for developing individual integrated care
models needed for enhancing and sustaining recovery in each substance abuser.
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CHAPTER 3: THE EFFECT OF CRANIAL ELECTROTHERAPY STIMULATION AS
A METHOD TO DECREASE ANXIETY SYMPTOMS FOLLOWING OPIATE AND
ALCOHOL WITHDRAWAL
Abstract
Background: Almost 35% of men suffering from alcohol or opiate dependence drop out prior to
completing residential programs of 30 days or less. Anxiety is often a quoted reason for early
dropout. Supplemental interventions designed to promote tenure in residential treatment are
sorely needed for men who are substance abusers.
Purpose: The purpose of this study was to determine if Cranial Electrotherapy Stimulation
(CES), which is FDA approved for the treatment of anxiety and depression, would decrease
anxiety in substance abusing men in early recovery.
Methods: A double blind experimental study using repeated measures and two treatment
conditions (intervention/active and control/placebo) was conducted over a period of 15 days
during the first 3 weeks of opiate/alcohol abstinence. Salivary Cortisol and state anxiety were
measured on the first and final day of CES treatment. Anxiety was also measured on all
participants at study enrollment and at 30 days.
Results: Fifty nine participants completed the study. Anxiety and cortisol responses improved in
both groups. While differences were not significant, the cortisol decrease was greater in the
active treatment group than in the placebo group. In addition there appeared to be a trending
downward in momentary anxiety as measured in the active group.
Conclusions: CES may be effective in reducing anxiety and cortisol response in this population;
however it was not demonstrated statistically in this study. Psychopharmacological medications
as well as placebo effect may have confounded the results. More research is needed in this area.
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Introduction
Substance abuse is an individual and public health problem that costs the United States
more than $0.5 trillion annually in health care, lost earnings, and associated crime or accidents
(National Institute of Drug Abuse [NIDA], 2012). A majority of substance abusers are men.
Indeed, over one quarter of the 8.5 million men arrested in 2010, were arrested for charges
relating directly to substance abuse (Bureau of Justice Statistics, 2012). Approximately 1 million
people access residential substance use treatment each year. Of these, two-thirds are men, many
of whom are referred directly from the Criminal Justice system (Substance Abuse and Mental
Health Services Administration [SAMHSA], 2012).
Men are more likely to abuse opiates and alcohol than women (SAMHSA, 2012) and
they also start substance abuse at a younger age than women. However, they enter treatment
later, making them at greater risk for poorer treatment outcomes, having less family support and
greater involvement with criminal activity (Grella & Joshi, 1999). Almost 35% drop out prior to
completing residential programs of 30 days or less (SAMHSA Office of Applied Studies, 2009).
Hence, supplemental interventions designed to promote tenure in residential treatment are sorely
needed for men who are substance abusers. The purpose of this study was to investigate whether
Cranial Electrotherapy Stimulation (CES) would decrease anxiety symptoms and increase
retention in treatment.
Background
Anxiety is the most common and disabling of the acute withdrawal symptoms
(McGuinness & Fogger, 2006) and has been identified as a significant reason for treatment
dropout and subsequent relapse (Levy, 2008). Anxiety generally peaks within two weeks of
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substance abstinence (Ganzel, Morris & Wethington, 2010; Sher, 2002), but may persist for
many months. Anxiety also affects individuals’ ability to learn and complete the cognitive tasks
needed to successfully complete residential treatment (Burriss, Ayers, Ginsberg, & Powell,
2008).
Anxiety symptoms are a product of continued sympathetic stimulation (Koob, 2005). In
the substance abuser, this occurs when the hypothalamic-pituitary-adrenal (HPA) axis is
stimulated by the neurohormones which are dysregulated during withdrawal of the substance of
abuse (Lovallo, 2006). Various medications are presently used to attenuate the anxiety
symptoms associated with this dysregulation in an effort to enhance program participation and
continuation in treatment. The most effective medications for relief of anxiety are the
benzodiazepines. However, medications in this class are not appropriate for use in a substance
abusing population as these medications, which have a high addictive potential, may create
further addictive behavior in these individuals (Casher, Gih, & Bess, 2011).
Other pharmaceutical agents approved for anxiety relief such as buspirone, hydroxyzine,
trazodone and doxepin have limited efficacy (Casher, Gih & Bess, 2011). In addition the
antihistamine and anticholinergic side effects of dry mouth and sleepiness may make them less
tolerable. Many other medications administered to treat anxiety are used “off label” and include
atypical antipsychotic and antiepileptic drugs (McGuinness & Fogger, 2006; Pollack et al.,
2008). Antipsychotic and antiepileptic medications decrease negative emotions, and also
attenuate cognitive processing and produce daytime sedation (Gilula & Kirsch, 2005). These
unwelcome side effects limit the cognitive resources available for developing anxiety
management skills.
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Providing recovering addicts with anxiety management skills during the early post-acute
withdrawal period is critical to sustaining recovery (Gil-Rivas, Prause,& Grella, 2009; Gossop,
Stewart, Browne, & Marsden, 2002). As substance-abuse treatment for men focuses on group
therapy and psychoeducation, participants need to be able to concentrate in order to participate
fully in treatment offered to acquire these skills. This underscores the need for new, nonpharmacological approaches to manage anxiety during the acute withdrawal period that occurs
early in the recovery process.
Cranial electrotherapy stimulation (CES) is a non-pharmacological approach to anxiety
management that may have promise to improve retention in residential treatment and decrease
early relapse. CES was developed in the Soviet Union in the 1950s, and first used in the United
States in the 1960s to treat insomnia via a method then referred to as electro sleep (Kirsh &
Smith, 2000). The technique was later approved by the U.S. Food and Drug Administration
(FDA) (2011) for use in the treatment of anxiety as well as depression and sleep disorders. CES
is presently used in the Veterans Administration System (Tan, Dao, Smith, Robinson, & Jensen,
2010), as well as in general practice for adjunctive treatment of anxiety, depression, and
insomnia.
It (CES) is believed to reduce anxiety symptoms through pulsed alpha wave alternating
current which affects neurotransmitters in the limbic system and subsequent downstream
engagement of the parasympathetic nervous system (Giordano, 2006; Gunther & Phillips, 2010).
This alpha wave stimulation ultimately results in decreased (more normalized) cortisol
production (Bystritsky, Kerwin, & Feusner, 2008; Kirsh & Gilula, 2007).
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The beneficial effect of alpha wave stimulation on cortisol regulation may be particularly
promising for individuals in substance abuse treatment as sustained elevations of cortisol are
known to occur during this time (Li et al. 2008; Lovallo, Dickensheets, Myers, Thomas, &
Nixon, 2000; Sinha et al. 2011). A blunted cortisol response (cortisol levels not quickly
returning to pre-stress baseline) to short stressful situations has also been identified in alcoholics
and polysubstance abusers (Daughters, Lejuez, Kahler, Strong, & Brown, 2005; Lovallo et al.,
2000). In addition, Daughters et al. (2005) noted that substance abusers were more likely to drop
out of residential treatment if cortisol did not return to the expected baseline after completing a
stressful task.
To date, no studies have addressed whether a more normalized (less blunted) cortisol
response occurs in early recovery when an individual is treated with a single episode of CES.
Nor have studies addressed whether a CES related change in the cortisol response is associated
with a momentary reduction in anxiety (i.e: state anxiety), or whether repeated use is associated
with a reduction in anxiety lasting a few days.
A Meta-analysis of 15 CES treatment studies (n=335) published by Kirsh and Gilula,
(2007) provides evidence of a therapeutic effect in decreasing anxiety and other somatic
symptoms (r = .65+8) among a variety of substance-abusing populations being treated in various
settings. CES treatment was found to be effective for relieving anxiety in a non-substance
abusing population with hour long treatments over several weeks (Bystritsky, Kerwin, &
Feusner, 2008, Barclay & Barclay, 2014). A positive effect was also identified during a single
treatment for state anxiety exacerbated by dental procedures (Winick, 2009). This suggests that
(1) a single treatment of one hour may decrease cortisol level as well as state anxiety, and (2)
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multiple treatments over several weeks may be effective in decreasing anxiety in substance
abusers during the time in residential treatment.
Purpose
The purpose of this study was to determine if Cranial Electrotherapy Stimulation (CES),
which is FDA approved for the treatment of anxiety, depression and insomnia, would decrease
anxiety in substance abusing men in early recovery. Decreased anxiety in residential treatment
has been identified as a factor associated with remaining in residential treatment (Hutchison,
2016. Chapter 4).
Method

Design
A double blind experimental study using repeated measures and two treatment conditions
(intervention/active and control/placebo) was conducted over a period of 15 days during the first
3 weeks of opiate/alcohol abstinence. Anxiety and PTSD symptoms were measured at study
enrollment. Anxiety and depression symptoms were measured at 30 days (study completion).

Study AIMS


AIM 1: to compare in men in early substance recovery treatment for substance abuse the
effects of Cranial Electrotherapy Stimulation or placebo on anxiety and depression.



AIM 2: to compare in men in early substance recovery treatment for substance abuse the
effects of Cranial Electrotherapy Stimulation or placebo on cortisol level.
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Setting and Sample
The setting for this study was a Level II residential treatment program for men which is
operated by the Center for Drug Free Living (CFDFL) and certified by the Commission on
Accreditation of Rehabilitation Facilities. Only the Level II program clients residing on campus
were eligible for study enrollment. A level II program was selected as this provides up to 6
hours of psychosocial support daily in a structured environment. The treatment program
includes daily group sessions with psychoeducation, as well as weekly individual counseling. In
this environment, participants could be monitored for compliance with the treatment protocol.
Participants were initially recruited during their stay in the medical detox facility when
the PI discussed the study during the weekly community meeting. All clients completing an
alcohol or opiate medical detox were eligible to participate if they met the administrative criteria
for admission into the Level II residential treatment program and intended to stay in treatment
for at least 30 days. Individuals with mental health disorders were not excluded if they were
considered appropriate for residential treatment. Exclusion criteria were: (1) having an
implantable electrical device (this exclusion criterion was recommended by the CES
manufacturer); (2) unable to read or understand English; (3) recent dental surgery or bleeding
oral lesions (blood in the salivary cortisol specimen affects accuracy of measurement). Four to
six individuals who met the study criteria were typically admitted every week. Approximately
five months were required to enroll 79 study participants.

Study Measures
A demographic questionnaire was used to assess age, education, race/ethnicity, housing
situation prior to admission, primary substance of abuse and mental health disorders prior to
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admission. Additional variables included chronic medications and previous residential treatment
admissions. Symptoms of PTSD and depression were also collected as independent variables.
The PTSD Checklist—Civilian Version (PCL-C) was used to assess for symptoms of
posttraumatic stress disorder (PTSD) which clients were presently experiencing Mental Illness
(Research, Education and Clinical Centers [MIRECC]. n.d.). This self-administered instrument
has been in general use for more than 20 years in both military and civilian populations (Orsillo,
2001). Scores of less than 29 are considered not significant for PTSD, while those above 45 are
considered of high enough severity for continuing with the assessment for the diagnosis of
PTSD. The PCL consists of 17 items identified with the diagnosis of PTSD in the DSM, and
uses a 5 point Likert scale. Internal consistency is high (r = .75) across studies in various
populations (Wilkins, Lang, & Norman, 2011).
Anxiety experienced since leaving the detox facility was measured using the Zung SAS
(Zung, 1971). This self-administered anxiety scale is used for identifying anxiety symptoms that
have occurred within the past few days. The Zung is a 20 item measure of somatic and
psychological symptoms reflecting on feelings over the identified time frame. Each item is
scored using a 4 point Likert scale with 5 items being reverse scored. Anxiety scores between 45
and 60 are considered moderate anxiety, and scores between 60 and 74 are considered severe
anxiety. A raw score of > 36 is clinically significant for difficulty carrying out normal work or
activities (Zung, 1980). The Zung has good reliability (r = .71, alpha = .798; Zung, 1971) and
content validity when compared to the Hamilton Anxiety scale (r =.75) (Sharpley & Christie,
2007). The Zung scale has been used in various populations for research and clinical assessment
since its development in 1971 (Sharpley & Christie, 2007).
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Depression was measured at 30 days in recovery treatment using the Patient Health
Questionnaire (PHQ-9). This depression scale was originally developed by Spitzer, Williams,
and Kroenke (1999) with a grant from Pfizer Inc. The PHQ-9 is a 9-item self-report measure
that assesses the nine depression symptoms from the DSM-IV depression criteria (Kroenke et al.,
2001). Each item is scored on a 4-point scale (0–3) and scores range from 0 to 27. Similar to the
Beck Depression Inventory (BDI), the summed scores can be used to describe the patient’s
symptoms in one of five interpretive categories: none (0–4), mild (5–9), moderate (10–14),
moderately severe (15–19), and severe (20–27). A cut-off score of > 10 is generally used to
identify individuals likely to have major depressive disorders (Kroenke, et al., 2001). The PHQ9 has been shown to be highly correlated (r =0.76) with the Beck Depression Inventory and has
good internal consistency (r =.87) when used in residential substance abuse treatment (Hepner,
Hunter, Edelen, Zhou & Watkins, 2009).
State anxiety was measured using the 6 item State-Trait Anxiety Inventory (STAI-6;
Marteau & Bekker, 1992). The STAI-6 is a self-administered measure of state anxiety. This 6item version of the Speilberger STAI (Tiuczek, Henriques, & Brown, 2009) correlates well with
the full (20 item state anxiety) STAI (r=.95) and has good internal consistency (alpha = .82) as
well as excellent construct validity in clinical populations (Court, Greenland, & Margrain, 2010).
Cortisol was collected using a commercially prepared self-collection kit designed to
measure salivary cortisol and was provided by Salimetrics (Salmetrics 2011), the laboratory
chosen to evaluate the cortisol levels. This laboratory provided support for collection and
shipment, in addition to performing salivary cortisol assays (Salimetrics, 2012). The average
morning cortisol level reported by Salmetrics (2012) for adult males between ages 31 and 50 is
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0.122 - 1.551. Salimetrics uses a duplicate sample of saliva and a highly sensitive immunoassay
which has a lower limit of sensitivity of 0.003ug/dl and a standard curve ranging from
0.012ug/dl to 3.0 ug/dl. The average intra-assay coefficient has a variation of 3.5% and interassay coefficient of variation of 5%. Serum and saliva samples show strong linear relationship (r
= .91, p < 0.0001) which is consistent with McCracken & Poland’s (1989) work indicating a
strong connection between salivary and circulating cortisol (r = .78, p < .03) when both are
measured over time within the same individual.

Procedure
Each participant had a uniquely numbered CES unit assigned to him on day 1 of the
treatment period. The unit was randomly pulled from the box of units by the PI when directions
for use were being reviewed prior to the first treatment. This unit was then labeled with his
name. Neither the participant nor the PI was aware of whether the unit was a placebo or active
CES unit. The participant picked up his unit each day, applied saline solution to the ear clips and
attached them to his ear lobes. He then turned on the unit as instructed and proceeded with
normal activities until he returned it to the storage bin an hour later when the unit automatically
turned off. At that time he signed the log book to validate time and length of use. The log book
was checked daily by the PI or the facility nurse to insure compliance with instructions.
The three week CES treatment period began during the first week following the medical
detox and continued for a total of 15 daily one hour sessions over the following three weeks. If
participants were unable to complete the number of treatments within this time frame they were
withdrawn from the study.
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Data Collection Procedures
Salivary Cortisol was collected on the first and final day of CES treatment, before and
after the daily CES treatment session scheduled for that day for all participants. Cortisol was
measured between 0815 and 0845 am and again between 0930 and 1000 am following
completion of the hour long treatment on these days. As morning cortisol levels usually peak
within 2 hours of arising and then gradually decrease during the day, collection at these time
points allowed for consistency between participants. State anxiety, using the STAI 6 was
collected at these same 4 time points.
Anxiety symptoms experienced during the past few days were measured using the Zung
SAS on all participants at study enrollment and at 30 days. PTSD symptoms, using the PCL-C,
were measured on admission. Depression, using the PHQ-9, was measured at 30 days as
recommended in the literature (Hepner et al. 2009).
Each participant received a gift card to a big-box retail store (Walmart) at two time
points: Completion of the second salivary cortisol and STAI-6 on the day one (first) treatment
session ($5), and after completion of the Zung SAS, and the PHQ-9 on day 30 of residential
treatment ($10).
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Recruitment of potential participants at
the Detox facility (n=79 males)

Excluded if not meeting
inclusion criteria

Admission to residential Program

Enrollment and collection of baseline data: Consent,
Demographics, PCL, Zung SAS,

On Day 1 of Treatment (day 2-4 after admission)
Participants randomly assigned a CES unit which was
either active or placebo, blinded to both the
participant and the PI

Collection of Salivary Cortisol and
STAI 6 (pre- treatment) at 9 am
One hour of treatment with double
blinded CES device
Collection of Salivary Cortisol and
STAI -6 (post-treatment) at 1030 am.
($5 gift card given to participant)

Continue daily treatment intervention with CES device for 15 treatments within 21 days. Repeat Salivary Cortisol and
STAI-6 pre and post final CES treatment session.

On day 30 of Residential Program - retake the Zung SAS (#2) and PHQ 9 completed. $10 Gift Card given to Participant
Study Termination

After completion of Zung SAS and PHQ-9 on day 30, the participant’s
participation in the study was terminated and he was given a final gift card .

Figure 1: Flow of Participants through the study
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Data Analysis
Descriptive statistics (e.g., mean, standard deviation, frequency, and percentage) were
calculated for all demographic variables to summarize sample characteristics and properties of
the key study variables, including the proportion of participants with and without PTSD and/or
depression in each study condition. Differences in the demographic characteristics of the
placebo and experimental group were investigated with Chi-square analysis for categorical data
and t tests for continuous variables. An alpha level of 0.05 was used in these analyses and in
those used to address study hypotheses and research questions.

Ethical Considerations
This study was approved through the University of Central Florida Institutional Review
Board. Participation in the study was voluntary and not a requisite for enrolling in residential
treatment. There were no significant adverse effects identified during the use of this CES device
during this study.
Results
A convenience sample of 79 adult male participants who met study criteria were
recruited for the study between October 2013 and April 2014. Approximately 110 individuals
were admitted into the residential treatment program for treatment of alcohol or opiate
dependence following inpatient detox during the study period; 81 volunteered for entry into the
study. Two individuals were subsequently withdrawn by the investigator due to severe medical
problems during the first few days in treatment. The remaining 79 were randomized into either
the control/placebo or experimental group.
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Of the 79 randomized participants, 19 subsequently dropped out of the study. One
participant asked to be withdrawn and eventually finished residential treatment. One participant
was withdrawn by the PI as he was unable to complete all requirements within the study time
constraints, and eventually dropped out of treatment. The remaining 17 participants either left
the program, or were terminated by the administration due to drug use (relapse) in the facility.
Sixty participants completed the required number of CES treatments and 57 completed the 30
day post treatment psychological inventories. The attrition rate was approximately 24%,
resulting in a sample for analysis of 57. Assuming a power of .80 and an alpha of .05, a sample
of 56 was estimated to be sufficient to detect a moderate (0.25) effect.

Sample Characteristics
There were no significant differences on the pretreatment demographic variables between
the active and the placebo group of study completers. Table 1 provides demographic data by
treatment group. The average age in the intervention group was 39 and 41 for the placebo group.
The majority of participants in both groups were European/White race, homeless, educated at the
high school level or higher and their primary substance of abuse were opiates.
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Table 2: Population demographics of study completers
Variable

Intervention n=29

Placebo
n=31

n(%)

n(%)

Age groups
Less than 30
31-50
Over 50

6 (10%)
15 (25%)
8 (13.3%)

10 (16.6%)
13 (21.6%)
8 (13.3%)

Race/Ethnicity
European/White
Hispanic
African American

21 (35%)
5(8.3%)
3 (5.0%)

20 (33.3%)
8 (13.3%)
3 (5.0%)

p value
for Χ2

Total
n=60
n(%)

p =.40
16 (26.6%)
28 (46.6%)
16 (26.6%)
p =.80

Living situation prior to treatment
Family or self
Living with parents
Transitional housing or friends
Homeless

6(10.0%)
0 (0.0 %)
5(8.3%)
18 (30.0%)

6(10.0%)
5 (8.3%)
6 (10.0%)
14 (23.3%)

Years of Education
< High School
GED
HS Diploma
college/trade/AA

4(6.6%)
9 (15.0%)
7 (11.6%)
9(15.0%)

7 (11.6%)
6 (10.0%)
9 (15.0%)
9 (15.0%)

Primary Substances of Abuse
Opiate
Alcohol
Poly substance with opiate

12 (20.0%)
9 (15.0%)
8 (13.3%)

12 (20%)
10 (16.6%)
9 (15%)

41 (68.3%)
13 (21.6%)
6 (10.6%)
p=.15
12 (20%)
5 (8.3%)
11 (18.3%)
32 (53.3%)
p=.62
11 (18.3%)
15 (25.0%)
16 (26.6%)
18 (30.0%)
p=.98
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24 (40%)
19 (31.6%)
17 (28.3%)

The mean age of the dropout group was 35 compared to 41 in the completers. All of the
participants in the drop out group were opiate dependent while 32% of the study completers had
a primary diagnosis of alcohol dependence. Opiate users are known to drop out earlier than
alcohol users as their symptoms are often more severe and protracted. Of interest is that
completers endorsed more PTSD symptoms but less anxiety symptoms on admission and there
was a difference between the STAI 1 and STAI 2 in these groups. The other demographic
markers of the participants were similar to that of the general population of clients admitted to
this program. Eleven of the 19 dropouts were in the active CES group.

Primary Outcome Measures.
The effect of CES treatment on generalized anxiety (Zung SAS), on state anxiety (STAI6), as well as on Depression (PHQ-9) was analyzed. There were 31 participants in the placebo
group and 29 in the experimental (active CES) group.
The participants had mean baseline Zung SAS scores of 43.55 (10.65) in the placebo
group and 44.66(11.21) in the active CES group. The Zung SAS at 30 days was 35.71 (10.6) in
the placebo group and 36.90 (10.38) in the CES group. Depression based on the PHQ-9 at 30
days (Study termination) was 8.46(6.06) in the placebo group and 8.31(6.02) in the active CES
group. The number of participants on antidepressants at day 30 in the placebo group was 10 and
15 in the active group. Twelve of these participants were on antidepressants prior to starting
treatment. There were no significant differences between groups (see Table 2).

54

Table 3: Effect of CES on Anxiety and Depression
Variable

Placebo CES
Mean and SD

Active CES
Mean and SD

P value for
Χ2

Zung SAS (Anxiety) on
Admission
Zung SAS (anxiety) at 30
days

43.58 (10.65)

44.66 (11.12)

.19

35.71 (10.60)

36.90 (10.38)

.63

Depression (PHQ-) at 30
days

8.46 (6.06)

8.31 (6.02)

.12

On antidepressants at 30
days

10

15

.15

STAI 6 prior to 1st CES
treatment
STAI 6 after 1st CES
treatment

12.94 (3.97)

13.90 (4.40)

.47

11.73 (3.95)

13.01 (4.12)

.67

STAI 6 prior to last CES
treatment
STAI 6 after last CES
treatment

11.51 (4.26)

11.10 (4.08)

.73

11.38 (3.56

10.38 (3.56)

.44

The STAI-6 at baseline (prior to any CES treatment) was 12.94(3.97) in the placebo
group and 13.90(4.40) in the active CES group. Following the first CES treatment, the results
were 11.73(3.95) in the placebo group and 13.10(4.12) in the active group respectively. On the
final day of CES treatment, the placebo group scored 11.51(4.26) and the active CES group
scored 11.10(4.08) prior to the treatment session. Following this final session the scores were
11.38(4.51) and 10.38(3.56). While these differences were not statistically significant at any
time point, greater improvement was seen in the experimental group compared to the placebo
group.
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Secondary Outcome Measures.
The effect of time and treatment on salivary cortisol levels was measured. Cortisol was
measured between 0815 and 0845 prior to CES treatment on the first and last day of CES use
(both placebo and active CES group) and again between 0930 and 1000, following completion of
the hour long treatment on these days. Mean (SD) baseline salivary cortisol in the placebo group
was .588 (.415) and decreased to .571 (.962) following the first treatment session. In the active
group the mean (SD) cortisol level was .386 (.287) prior to treatment, and decreased to .302
(.254) following the initial session. On the final day of CES treatment, the placebo group
measured .328 (.208) prior to treatment and .201(.129) following the session. The active CES
group measured .340 (.193) and decreased to .168(.926) following the session (see Table 3).
While these differences were not statistically significant, some interesting trends were noted.
Salivary cortisol decreased in all of the participants following the initial session and continued to
decrease until the completion of the program. Importantly, while not statistically significant, the
active CES group showed a greater downward trend in cortisol levels.

Table 4: Effect of CES on Salivary Cortisol
Cortisol collection time

Placebo
Mean and SD

Intervention
Mean and SD

P value of Χ2

Cortisol before 1st CES treatment
Cortisol after 1st CES treatment

.588 (.415)
.571 (.962)

.386 (287)
.302 (.254

.40
.40

Cortisol before last CES treatment
Cortisol after last CES treatment

.328 (.208)
.201 (.129)

.340 (.193)
.168 (.926)

.46
.51

Discussion
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While this double blinded study identified no statistically significant differences in the
response to anxiety between the experimental (CES) group and the placebo group at study
conclusion, some important trends were noted. The cortisol decrease was greater in the active
treatment group than in the placebo group. In addition there appeared to be a trending downward
in momentary anxiety as measured by the STAI 6 in the active group at the end of the treatment
phase. These differences might have been more evident in a larger study group and/or in a group
focused on a single chemical of abuse: either alcohol or opiate.
The opiate dependent participants were generally younger and appeared to be less able to
complete treatment as this was the only group who dropped out of the study. However, there
may be other, unidentified factors affecting the results. All participants who completed the study
were enthusiastic about participation and needed few reminders to come in and use the devices
each day.
Since participants did not know if they were receiving the CES or the placebo, many
thought they were in the experimental group and felt less anxious. There was also positive
reinforcement within the study as each participant received increased social support due to
multiple daily short interactions with the PI, her assistant or the facility nurse which could have
influenced the outcomes. If multiple arms had been used in this study such as a treatment,
placebo and control group the results might have been statistically significant. However,
participants might have been more difficult to recruit into a control group (treatment as usual) if
there was a perceived benefit to those in the active or placebo arms. Also, the effect of increased
social support from providers or the study team may have been a factor on the decrease in
anxiety in both groups over the 30 day period. The change in anxiety as manifested on the Zung
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SAS was similar to that of a previous study in this population (Hutchison, 2016). Also of
interest, at 30 days in the program, neither group endorsed greater than mild depressive
symptoms (PhQ-9 was less than 10). However almost half the participants were on
antidepressants: more participants in the active treatment group were on antidepressants when
compared to the placebo group. The difference between groups was not significant as any of
these participants were already on antidepressants when initially enrolled in the study. Different
results may have been obtained if none of the participants were on psychopharmacological
medications.

Implications
The demographic differences between the dropouts and program completers are
significant in that only opiate users dropped out and were a few years younger (35 vs. 41) than
those competing the study. Opiate, alcohol and opiate/alcohol combined users behave differently
and perhaps should be studied separately. It may be important to recognize these differences, not
only in research but also in treatment programs as the cultural and social differences in these
populations may affect outcomes.
Although the use of CES in this study did not show significant differences between the
two groups in this study, the participants were engaged in an activity that they perceived to be of
benefit. More research is needed in this area. In addition, using CES as an option for treatment
in specific individuals who identify high anxiety symptoms on program arrival may affect their
treatment outcome. Individuals who have a preexisting diagnosis of generalized anxiety may
also benefit from prolonged use. There was considerable variation was noted between individual
responses in this study. An open label study might identify these individuals and their associated
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individual characteristics. More research is needed to identify these characteristics and
relationship to CES use.

Study Strengths and Limitations
This was a small double blinded study at a single treatment program and study inclusion
criteria were very broad. However, because the participants were randomized to either
intervention or control groups, the variability between and within groups should have been
minimized. An additional confounder was that the participants were treated with
pharmaceuticals for anxiety, sleep and depression when indicated and this may have affected
individual cortisol and CES response.
Conclusion
Although CES has been used for many years in the treatment of anxiety, in this study, the
effect of CES was not significantly greater than that of the placebo in this population. However,
more research is needed in this area as the results may have been mitigated by the large number
of variables. Also, there was trending towards improvement of symptoms. In future research,
narrowing the criteria for study admission might decrease the number of variables. Limiting the
study to participants with a single substance of abuse and a high anxiety level on admission
could provide a narrower focus on anxiety outcome. An additional study measuring cortisol in a
control group of substance abusing men awaiting residential placement and within a treatment as
usual group of men in the residential recovery program, measured at the same time points as
done in this study would be helpful. This would determine if the gradual decrease in cortisol
levels noted over time was an effect of the treatment/placebo or a normal effect of time in

59

substance abuse recovery or another unknown factor. A slow normalizing of cortisol response is
expected. Finally, in a future study, multiple arms in a trial, such as treatment, placebo and
control group, might result in statistically significant outcomes.
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CHAPTER 4: TRANSLATIONAL RESEARCH APPROACH FOR NURSE CLINICIANS
EFFECT OF ANXIETY ON SUBSTANCE ABUSE TREATMENT AND EARLY
RELAPSE IN RESIDENTIAL SUBSTANCE ABUSE TREATMENT

Abstract
Anxiety is a recognized, co-occurring disorder associated with substance abuse, and is a
prominent negative emotion experienced by many patients during post-acute withdrawal from
opiates and alcohol. Although anxiety as a factor in relapse has been measured in longitudinal
studies, little data exists on measuring anxiety during the first few weeks following medically
assisted withdrawal, or how anxiety affects treatment and relapse during this critical time in
residential treatment. The aims of this study were to determine whether (1) patients who fail to
complete residential treatment differ in level of anxiety symptoms on admission from those who
complete treatment (2) patients who relapse, or leave residential treatment prior to completion,
have higher anxiety scores prior to discharge than individuals who complete treatment, (3) selfreport of PTSD symptoms affects change in anxiety symptoms during the first 60 days of
substance abuse recovery, and (4) reported PTSD is a significant factor in drop-out from
residential treatment prior to completion.
Methods: A prospective study was conducted with 53 males entering a residential program
immediately following medical detox from alcohol or opiates. A one group repeated measures
design was used with anxiety data (Zung SAS) collected at entry, 30, and 60 days.
Results: While the relationship between Zung anxiety scores on admission and leaving treatment
were not significant (p-value =.96), there was a significant difference between the last measured
anxiety score and leaving treatment prior to completion (p-value < .02) when compared to
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treatment completers. While not significant, there was a trend in the slowing of the rate of
anxiety diminishing in those with PTSD symptoms and those without (p >.08). However, men
with PTSD did not leave treatment prior to completion more frequently than those without
PTSD.
Conclusion: Anxiety is a significant factor in relapse during the first two months of treatment.
Individuals with persistent anxiety were less likely to complete treatment than those whose
anxiety remitted during the first few weeks after detox. Reported PTSD was not an independent
risk factor in leaving treatment prior to completion.

Introduction
Empirical evidence suggests that most individuals will have significant anxiety during the
initial weeks of treatment and early recovery from opiate and alcohol dependence (Schuckit &
Hesselboch, 1994, Sher, 2002). Stress and anxiety have been identified as high risk reasons for
relapse (Levy, 2008). Anxiety is a common co-occurring disorder in substance abusers (Smith &
Book, 2008) and a multisystem response to a perceived threat or danger, generally produced by
somatic symptoms in the present and cognitively by anticipation of stressful events in the future.
It is the most prominent negative emotional state which many patients endure during the postacute withdrawal period immediately following medical detox (Colasanti, Rabiner, LingfordHughes, & Nutt, 2010, McGuinness & Fogger, 2006).
The anxiety symptoms commonly associated with substance abuse withdrawal during the
first few weeks of abstinence are characterized by insomnia (Monti & Monti, 2000, Thakker
20011), generalized irritability (Koob & Le Moal, 2005), low distress tolerance (Daughters,
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,Lejuez, Kahler, Strong, & Brown, 2005), difficulty with cognitive processing (Eysenck,
Derakshan, Santos & Calvo 2007) and exacerbated by hypersensitivity to pain (Vachon-Presseau
et al., 2013). The amount and duration of these anxiety symptoms during this post-acute
withdrawal period reflect a variety of neurochemical changes in the body, the extent of which are
manifested by the individual’s personality, life experiences and genetic makeup (Nemeroff,
1998), as well as the type and amount of preceding drug use.
During the post-acute withdrawal period, many anxiety symptoms abate without
treatment (DSM-5) over 3 to 6 weeks. It is not known whether acute anxiety symptoms in the
immediate post withdrawal period abate at a different rate in men who endorse symptoms of Post
Traumatic Stress Disorder (PTSD) than in those who do not (Gil-Rivas, Prause, & Grella, 2009).
Nor have studies addressed whether a high level of anxiety during the first week following detox
is a risk factor for relapse over the next two months. However, it is known that the risk of
relapse due to anxiety, when present, persists far beyond these first two months in recovery
(Heilig, Elgi, Crabbe, & Becker, 2010). In a prospective study of substance abusers in recovery
(Charney, Palacios-Boix, Negrete, Dobkin, & Gill, 2005), 48% presented with anxiety during the
immediate post withdrawal period. Of these, only 40% of them were abstinent at 6 months. This
evidence suggests that increased anxiety at intake is a predictor of treatment outcome.
The negative effect of lifetime trauma such as childhood abuse (Elliot et al., 2014) has
also been identified as an increased risk factor associated with relapse and continued substance
abuse (Lejuez et al., 2008, Darke, 2013). In a convenience study of male substance abusers (GilRivas et al., 2009), 73% had a preexisting diagnosis of mood disorder, and 52% had a life time
diagnosis of PTSD. Almost 27% admitted to a lifetime history of opiate dependence and more
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than 70% to alcohol dependence. Anxiety was measured at three time points: within 48 hours of
admission, at 3 months and at 12 months. Anxiety was highly correlated between all the time
points (r = .71, P < .001). Relapse rates of 45.3 % at 3 months and 52.6% at 12 months were
identified in those with PTSD. Anxiety symptoms did not decrease between 6 and 12 months
after start of treatment.
Effect of Treatment on Anxiety
Relieving anxiety, and the commonly associated somatic symptoms, as well as
addressing the psychosocial components of addiction, are paramount for maintaining patients in
treatment and reducing dropout and relapse. In early recovery, the inability to attend to what is
being taught also increases the risk of relapse during this initial period because learning coping
skills and increasing self-efficacy are critical components of recovery. Anxiety has been shown
to decrease attention and ability to successfully complete tasks. Studies have confirmed this in
alcoholics in early recovery (Daughters et al., 2005). A study in college students (Chapell et al.,
2005) also identified that with increased anxiety, comprehension in learning new material
decreases.
A meta-analysis of anxiety and its relationship to performing creative tasks, suggested
that there is a significant negative relationship between increase in anxiety and the ability to
complete verbal tasks (p <.001) (Byron & Khazanchi, 2011). When individuals devote more
cognitive resources to their anxiety and its symptoms, less personal resources are available for
creative expression. Anxiety is also a component of low distress tolerance (Keough, Riccardi,
Timpano, Mitchel, & Schmidt, 2010). Daughters et al. (2005) addressed the impact of low
distress tolerance in substance abusers during early recovery (n = 89, 62% male, almost 90%
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alcohol or poly substance abusers, 80% high school or less) in a period of 6 weeks of inpatient
treatment. A significant reduction in task completion was noted (r = .27), (p =.01) between
those participants who were tested more closely to (1-2 weeks post) detox when compared to
those who were tested 5 to 6 weeks post-detox.
Anxiety in Integrative Treatment
An integrative approach to substance abuse treatment which focuses on enhancing coping
skills, relapse prevention, psycho-education and 12 step programs, as well as psychotherapy in
individual sessions for both the substance abuse and concurrent mental health disorders has been
supported for many years (Miller, Sorensen, Selzer, & Brigham, 2006). Hesse (2009) in a
systematic review focusing on anxiety and depression in substance use treatment, found some
support for integrated psychotherapy in the treatment of depression and substance abuse.
However, due to a paucity of similar studies, a meta-analysis was unable to be completed on
anxiety during substance abuse recovery treatment. Five studies were identified, which met
criteria, but measurement methods were dissimilar. In these studies there was little evidence to
suggest that non-somatic or specialized treatment of anxiety disorders yielded any significant
benefit during early recovery. However, there was a recommendation that more research was
needed in this area (Hesse, 2009). Therefore, the purpose of this study was to identify the level
of anxiety experienced by men in early recovery in an integrative substance abuse program.
The aims of this study were to determine whether (1) patients who fail to complete
residential treatment differ in level of anxiety symptoms on admission from those who complete
treatment, (2) patients who relapse, or leave residential treatment prior to completion, have
higher anxiety scores prior to discharge than individuals who complete treatment, (3) self-report
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of PTSD symptoms affects change in anxiety symptoms during the first 60 days of substance
abuse recovery, and (4) reported PTSD is a significant factor in drop-out from residential prior to
treatment completion.
Method

Design
This study used a one group repeated measures design with anxiety data collected at
entry, 30 days, 60 days, and at discharge. Symptoms of PTSD were measured at intake and
correlated with anxiety measures at each time point.

Setting
The setting for this study was a Level II residential treatment program operated by the
Center for Drug Free Living (CFDFL) and certified by the Commission on Accreditation of
Rehabilitation Facilities. This Level II program provided up to 6 hours of psychosocial support
daily in a structured environment. The treatment program included daily group sessions with
psychoeducation, treatment with psychopharmaceuticals as needed, as well as weekly individual
counseling. This model of integrated treatment is the present standard of care for substance
abuse treatment. All residents admitted to the Level II program were referred directly from the
associated detox facility. The average length of stay in the program was 60 days but varied from
30 to 90 days.
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Enrollment and Duration of Study
A total of 53 men who met study criteria of either opiate or alcohol dependence were
enrolled over 12 weeks between 1 January 2012 and 5 May 2012. Each participant had
completed either an opiate (63%, n = 33) or alcohol (37%, n = 20) medical detox in the week
prior to admission.

Required Sample Size
Attrition rate was 26 % resulting in a sample of analysis of 39 at 30 days of treatment.
Assuming a power of .80 and an alpha of .05, a sample of 39 was sufficient to detect a moderate
effect.

Procedures
The study was discussed with all potential participants by the principal investigator (PI)
at the Detox facility’s weekly community meeting. Participants were recruited on arrival at the
residential treatment facility and 53 participants were enrolled. Within 48 hours of arrival at the
program, the PI met with interested clients, obtained informed consent and gave the client a copy
of the signed consent. The participants then completed the entry demographic questionnaire and
the PTSD Checklist –Civilian version (PCL-C). Participants also completed the baseline anxiety
(Zung SAS) inventory during a clinical interview with the PI on the same day study enrollment
was completed. On day 28-30 and on day 55-60 of the program, the participants completed the
Zung SAS again if they were still enrolled in treatment. Participants remaining in residential
treatment also completed the final Zung SAS at 90 days (n = 3). If participants did not wish to
be contacted, or left without notice, this was noted on the discharge or final questionnaire and
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participation in the study was terminated. The PI gave all the participants who completed the
study a $10 gift card to a local super market or super store at the time of their final data
collection.
Study measures
Demographics: A demographic questionnaire was used to assess age, education,
race/ethnicity, housing situation prior to admission, primary substance of abuse and mental
health disorders prior to admission. Medications being taken on admission and at 30 days were
obtained from the medical record.
Anxiety: Anxiety experienced over the past few days was measured using the Zung SAS.
This 20 item self-administered anxiety scale is used for identifying somatic and psychological
anxiety symptoms that have occurred within the past few days. Each item is scored as a 4 point
Likert scale with 5 items being reverse scored. Anxiety scores between 45 and 60 are considered
moderate anxiety, and scores between 60 and 74 are considered severe anxiety. A raw score of >
36 is clinically significant for difficulty carrying out normal work or activities (Zung, 1980). The
Zung score (Zung, 1971) has good reliability (r = .71, alpha = .798) and content validity when
compared to the Hamilton Anxiety scale (r =.75. Zung, 1971). The Zung scale has been used in
various populations for research and clinical assessment since its development in 1971 (Sharpley
& Christie, 2007, Liao et al.2011).
PTSD: The PTSD Checklist—Civilian Version (PCL-C) was used to assess for
symptoms of PTSD. This self-administered instrument has been in general use for more than 20
years in both military and civilian populations (Orsillo, 2001). Scores of less than 29 are
considered not significant for PTSD, while those above 45 are considered of high enough

74

severity for continuing with the assessment for the diagnosis of PTSD. The PCL consists of 17
items identified with the diagnosis of PTSD in the DSM, and uses a 5 point Likert scale. Internal
consistency is high (r = .75) across studies in various populations (Wilkins, Lang & Norman,
2011).
Data Analysis
Descriptive statistics (e.g. mean, S.D., frequency and %) were calculated on demographic
variables and included presence or absence of PTSD symptoms. The key study variables of
anxiety and treatment completion were also compared between the group who reported PTSD
symptoms and the group who did not. Research questions were answered using Pearson r
correlation or t-test to identify differences in the anxiety scores between time periods.
Results
All 53 participants completed the baseline data collection. Two participants (3.7%) left
treatment within the first week, and an additional 3 (5.6%) left the second week. At 30 days, a
total of 13 (24.1%) were no longer in treatment. Three were discharged after successful
completion and 10 left without notice or were discharged due to drug use on property (18%).
Only 3 were available to complete a final anxiety inventory at 90 days. A total of 15(28.3%)
participants dropped out of treatment prior to completion.
Fifty-three participants completed baseline data and were between the ages of 18 and 63,
with a majority (>70%) between ages 25-50 years. The majority of participants self- identified
as white, homeless or lived with friends, and were educated at the high school level or higher
(see Table1). Forty-nine percent (n=17) reported poly substance use with opiates and 38% (20)
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were previously diagnosed with a mental health disorder. High levels of anxiety were reported
in 34% (n=18) of participants. A score of >30 on the PCL was noted on 84% (n=48) of men and
43% (n=23) reported PTSD symptoms in the high range (>50).
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Table 5: Population demographics on admission
Male (n= 53 )
Age group [n (%)]
Less than 25
26-35
36-50
Over 50

6 (11.3%)
14 (26.4%)
24 (45.3%)
9 (17.1%)

Race/Ethnicity [n (%)]
European/White
Hispanic
African American

36 (67.9%)
12 (22.6%)
2 (2.5%)

Living situation prior to treatment [n(%)]
Family or self
Living with parents
Transitional housing or friends
Homeless

15 (28.3%)
7 (13.2%)
8(15.1%)
23 (43.4%)

Years of Education
< High School
GED
HS Diploma
college/trade/AA

9 (17.0%)
9 (17.0%)
16 (30.2%)
19(33.8%)

Primary Substances of Abuse [n (%)]
Opiate only
Alcohol only
Poly substance with opiate

16 (13.2%)
20 (37.7%)
17 (49%)

Mental Health Disorders (pre admission)

20 (37.7%)

Zung less than 37 -low anxiety [n (%)]

16 (30.2%)

Zung greater than 50 – high Anxiety [n (%)]

18 (34.0%)

PCL greater than 50 –High [n (%)]

23 (43%)

PCL greater than 40 Med (n (%)}

40 (75%)

PCL greater than 30 Low [n (%)]

48 (84.2%)
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Anxiety scores were consistent with empirical evidence which identifies a sharp decrease in
anxiety by 30 days post detox with a general flattening of anxiety symptoms in the following 30
days (Table 2). The correlation between scores on admission and scores at 30 days (r = .59) and
60 days (r = .64) was strong.

Table 6: Anxiety scores at three time points
Admission

30 day

60 day

N=
53
39
21
Mean (SD)
43.6(12.0)
34.5(8.7)
35.9(12.2)
______________________________________________________________________________

The difference between anxiety level at admission and completing or leaving treatment
early was not significant (p>.96). There was a significant difference (t=2.36; p <02) between last
anxiety score collected and leaving treatment early. Participants who left treatment early
reported higher anxiety.
There was a positive correlation between endorsement of PTSD symptoms (PCL-C
greater than 30) and endorsement of anxiety symptoms (Zung SAS) on admission (r = .49)
Correlation was even greater with a PCL greater than 50 (r = .54). While not significant, a trend
in the slowing of the rate of anxiety diminishing in those with PTSD symptoms and those
without (p >.08) was evident. However, men with PTSD did not leave treatment prior to
completion more frequently than those without PTSD.
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Discussion
Elevated anxiety symptoms in patients leaving treatment prior to completion of treatment
was found to be more significant than the level of anxiety participants reported on admission to
residential treatment following medical detox. Anxiety associated with the common symptoms
of alcohol and opiate withdrawal usually remits within 3-6 weeks (Brady, Haynes, Hartwell, &
Killeen, 2013). Hence there has been less interest in research treatment during this period
although more than 25% of clients admitted to treatment drop out during this period. Although
patients with self-reported PTSD symptoms had a slightly slower rate of anxiety symptoms
diminishing, it did not affect their length of time in treatment. Whether the PTSD was childhood
or adult onset, which may have been a variable, was not measured.
Factors within an integrative program may also contribute to continued anxiety during
residential treatment. High social anxiety was identified as a predictor of early drop-out,
especially in recovery programs, where much group work was expected (Lejuez, et al. 2008).
Low distress tolerance (Daughters et al 2005) and high anxiety sensitivity (Lejuez, et al. 2008)
may also contribute to sustained anxiety in a residential setting where task completion and group
participation is expected. The impact of PTSD and its association with substance abuse is well
recognized. Gil-Rivas et al. (2009) noted that more than 45% of patients with PTSD in recovery
relapsed within 3 months. Therapy involving previous life trauma may increase anxiety (Kelly
& Daley, 2013). Individual trauma is often addressed in both individual therapy as well as in
groups and is viewed as a necessary step in recovery treatment (Smith & Book, 2008). An
individual who has difficulty dealing with these thoughts and emotions may also have increased
anxiety which could contribute to early dropout.
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The presence and effect of other preexisting anxiety disorders must also be considered,
and when recognized, treated (Kelly & Daley, 2013). Almost 50% of patients with substance use
disorders have self-reported generalized anxiety starting in late adolescence or earlier. This is
usually the rationale used for their addictive disorder, often described as self-medication (Darke,
2013). It is also well documented in history that alcohol and opiates have been used for
millennia to reduce anxiety and associated stress symptoms and is the most effective coping
mechanism these individuals have developed. When anxiety becomes intolerable, persons with
addictive disorders revert to behavior which brings relief (Brady, Haynes, Hartwell, & Killeen,
2013). This is relapse which was identified as the most common reason for participants leaving
treatment early in this study. Anxiety stemming from these underlying causes is much less likely
to remit during the early weeks of recovery than anxiety associated with the common symptoms
of alcohol and opiate withdrawal (Brady et al., 2013).
This study addressed the symptoms of anxiety in early recovery. Relief of anxiety during
this period is critical for enhancing learning and building coping skills. It is well recognized that
the longer an individual stays in treatment, the better his chances of remaining in recovery
(McLellan & McKay, 2003). However in the present day managed-care environment, 30 days is
usually the maximum allowed time for residential treatment. This research study presents an
argument for identifying and initiating treatment for underlying anxiety disorders early in the
recovery process, as well as treating associated somatic complaints. This will allow for
maximum use of time in treatment to develop the internal tools and lifestyle changes needed to
enhance potential for recovery.
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Limitations
This was a focused study of anxiety in men at a single residential recovery program.
With the exception of PTSD symptoms, related variables were not considered. These include
depression which is highly correlated with anxiety but was not measured in this study, as well as
a history of childhood trauma. The psychotherapy method used by individual therapists or case
managers was not identified, nor was the depth of the therapeutic relationship, both of which
could have impacted level of anxiety. The study was underpowered and limited to individuals
with primary alcohol or opiate use disorders. However, many were poly-substance abusers and
also may have had other medical or mood disorders which could have affected outcomes in a
larger study. Of interest, most participants who left the residential program early were
unavailable to complete follow up anxiety scales and were unwilling to complete questionnaires
prior to leaving. Contact phone numbers had often been disconnected or the individual
answering the phone was unaware of the participant’s whereabouts. Anecdotally, many of the
participants returned to detox in the following months and related their stories regarding relapse.
Conclusion
Anxiety is a significant factor in relapse during the first months of substance abuse
recovery. Individuals with persistent anxiety are less likely to complete treatment than those
whose anxiety remits during the first few days or weeks after detox. Post-Traumatic Stress
Disorder is a significant variable in substance abuse and in this study it appears that it may
influence the course of anxiety symptom degradation.
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Recommendations
More research is needed to identify methods of decreasing and sustaining decreases in
anxiety very early in recovery in order to enhance program retention and ultimately maintain
substance abuse recovery. There is a need for more study on the integration of psychotherapy
such as motivational interviewing and non-sedating pharmacotherapy such as long acting
naltrexone as a means to decrease anxiety during the initial weeks of treatment. This is the time
when anxiety peaks and dropout from treatment is most likely. Early interventions are critical
for enhancing learning and sustaining desire for recovery through decreasing anxiety symptoms
and so enabling the substance abuser to apply the adaptive behaviors learned in therapy to their
own lives. Complementary and alternative medications/treatments (CAM), as well as somatic
therapies now being researched, may also have a role in decreasing anxiety without the sedating
effect often seen with psychopharmacotherapy. Individualized treatment should also include
genetic testing for identifying sensitivities to medications. This would assist in prescribing the
most likely effective pharmacotherapy for the individual early in treatment.
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Self-Administered State-Trait Anxiety Inventory (STAI-6)*
Study Number

_______

Date _ ____

A number of statements that people have used to describe themselves are given below.
Read each statement and then circle the most appropriate number to the right of the statement to
indicate how you feel right now, at this moment. There are no right or wrong answers. Do not
spend too much time on any one statement but give the answer that seems to describe your
present feelings best.
Not at all

Somewhat

Moderately

Very much

1. I feel calm

1

2

3

4

2. I am tense

1

2

3

4

3. I feel upset

1

2

3

4

4. I am relaxed

1

2

3

4

5. I feel content

1

2

3

4

6. I am worried

1

2

3

4

Please make sure that you have answered all the questions.
Note. * Adapted from “The development of a six-item short-form of the state scale of the
Spielberger State-Trait Anxiety Inventory (STAI),” by T. M. Marteau and H. Bekker, 1992,
British Journal of Clinical Psychology, 31, p. 306. Copyright 1992 by the British Psychological
Society. Reprinted with permission.
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strategies do early adolescent latino girls use? Journal of early adolescence. 35(4). 562580. Doi: 10.1177/0272431614544962

PRESENTATIONS
Hutchison, J.M. (2012). Anxiety in substance abuse treatment and relationship to early relapse.
Paper presented at the Center for Drug Free Living, Orlando, Fl. September
Hutchison, J.M. (2012). Measuring intentions to resist peer pressure. Paper presented at the
annual meeting of the Southern Nursing Research Society. New Orleans LA, Feb. 25
Hutchison, J.M. (2005). Short detoxification for opiate dependent patients using buprenorphine.
Poster presented at the annual meeting of the Health Care for the Homeless National
Conference, Washington DC, June.
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Central Florida Nurse Practitioner Counsel
American Nurses Association
Florida Nurse Association
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